Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/CD22 Dual Target CAR-T Cells in Relapsed/Refractory B-ALL
NCT04723901Phase 2Unknown
- Sponsor
- Shenzhen University General Hospital
- Start
- Oct 2020
- Primary completion
- Dec 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD19/CD22 dual-target CAR-T cells (Shenzhen University General Hospital) in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Shenzhen University General Hospital. Status: unknown.
02
Drugs
CD19/CD22 dual-target CAR-T cells (Shenzhen University General Hospital)
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04723901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04723901.